AI Predictor for TNBC
Triple-Negative Breast Cancer
Key Facts
About PathomIQ
PathomIQ is pioneering an AI-driven, interpretable multiomics platform in the diagnostics sector, focusing on transforming precision oncology. Its core asset is a first-of-its-kind phenotype atlas trained on thousands of histopathology slides with corresponding genomic data, enabling the prediction of therapy response, metastasis risk, and gene mutations from routine tissue images. The company positions its solution as a faster, more cost-effective, and tissue-preserving alternative to standalone genomic assays, with demonstrated applications in prostate, triple-negative breast, and ER+/HER2- breast cancers. PathomIQ is a private, likely pre-revenue company seeking to establish its AI-powered predictive tests as a new standard in clinical decision support.
View full company profileTherapeutic Areas
Other Triple-Negative Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CB-839 (Telaglenastat) | Calithera Biosciences | Phase 2 |
| RejuverSen Antibody | Centenara Labs | Pre-Clinical |
| FlowVax BreastCA | Flow Pharma | Pre-clinical |
| Undisclosed circRNA Program | CircNova | Pre-clinical |
| Radiolabeled hTAB004 (Therapeutic) | OncoTAb | Preclinical |
| TNBC Biomarker/Target Discovery | CogNano | Preclinical (Mouse Studies) |